Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DEBN
- Development stage
- Preclinical
- Lead developer
- DEBN
- Modality
- Small Molecules
- Administration
- Percutaneous
01
Overview
DEBN (Drug-Eluting Biopsy Needle) is a drug-device combination consisting of a polymer-coated biopsy needle and anesthesia needle designed to prevent infectious complications following transrectal ultrasound-guided prostate biopsy (TRUS-Bx). Developed by Orphinic Scientific and its portfolio company DEBN, the device is coated with a polymer (such as polyvinyl alcohol) that elutes antibiotics—specifically amikacin and/or ciprofloxacin—directly into the prostate tissue during the procedure. This localized delivery provides targeted antimicrobial prophylaxis, reducing the risk of infection and sepsis without the need for systemic administration or hospitalization.
- Other names
- Drug-Eluting Biopsy Needle
02
Targets
Bacterial RibosomeDNA gyraseTopo IV (Bacterial Topoisomerase IV)
Beyond the preview
Go deeper on DEBN.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DEBN.